Barclays PLC Adc Therapeutics Sa Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Barclays PLC holds 130,460 shares of ADCT stock, worth $516,621. This represents 0.0% of its overall portfolio holdings.
Number of Shares
130,460
Previous 145,407
10.28%
Holding current value
$516,621
Previous $390,000
33.59%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ADCT
# of Institutions
110Shares Held
67.3MCall Options Held
39.8KPut Options Held
68.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Morgan Stanley New York, NY3.67MShares$14.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...